Contribute Try STAT+ Today

Two former Alexion executives, both of whom resigned in the middle of a scandal two years ago, are starting a new biotech company — one with ambitious goals in cell and gene therapy, according to a new slide deck obtained by STAT.

The presentation provides some of the first details about the secretive new company, which its founders, including David Hallal and Vikas Sinha, are calling ElevateBio. They haven’t yet publicly discussed its existence or launched a website.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I fail to see why this is newsworthy. So two guys resign from Alexion and might or might not be guilty of something (article does not make it clear) but stat decides to leak a slide deck with “confidential and proprietary” marked on every slide showing a detailed map of the lab space and offices (with potential security implications for everyone that works there).

Comments are closed.